Doga Gulhan

Assistant Professor
doga_gulhan.jpg
MGH Cancer CenterCNY 149 13th StreetCharlestown, MA 02129
Lab Website
Publications

Doga is the Principal Investigator of the Gulhan Lab at the Krantz Family Center for Cancer Research at Mass General Hospital (MGH) and an Assistant Professor of Medicine and of Biomedical Informatics (secondary) at Harvard Medical School (HMS). She received her Bachelor of Science in Physics from Bilkent University, completed her Ph.D. in high-energy physics at the Massachusetts Institute of Technology, and worked as a Research Fellow at CERN. After transitioning to biomedical informatics, she joined the Park Lab in HMS’s Department of Biomedical Informatics as a postdoctoral fellow. There, she studied mutational processes and the immunogenomic consequences of DNA repair deficiencies. She developed algorithms that expanded the clinical and biological applications of mutational signature analysis and collaborated with clinical teams to apply signatures of DNA repair deficiency as biomarkers.

Since establishing her independent laboratory in 2023, Doga has built a research program around understanding cancer as a dynamic disease: how tumor cells evolve, change their transcriptional programs, and interact with the body during disease progression and treatment. Her laboratory integrates statistical modeling and machine learning with tissue and liquid biopsy profiling to connect cancer’s molecular history with its changing behavior, with a translational focus on drug resistance and metastasis.

A central ambition is to follow this evolving biology through blood. The lab views cell-free DNA as a systemic readout of cancer and its interactions with the host, carrying signals from tumor cells, immune cells, and other tissues. It develops computational methods that integrate fragmentomic, genomic, and methylation information to infer tissue contributions, gene-expression programs, and tumor molecular features from a single blood sample. By combining these readouts, the team seeks to understand how genomic alterations, adaptive changes in tumor cell state, and interactions with the microenvironment and other host tissues contribute to treatment resistance. The goal is to translate this integrated view into biomarkers for earlier detection, treatment selection, and longitudinal monitoring of disease progression and emerging resistance.

Complementary studies in tissue and single cells investigate the evolutionary and cellular processes underlying these circulating signals. The lab develops mutation-timing methods to infer the order of genomic events and analyzes samples collected across anatomical sites and time points to reconstruct how tumors diversify and spread. For mapping out the trajectories in earlies stages of cancer development, single-cell long-read sequencing connects genetic alterations with transcriptional states. Together, these approaches link the history of a cancer with its capacity to adapt and provide a foundation for interpreting its changing signals in blood.